Kaken Pharmaceutical Co. Ltd
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regrot… Read more
Market Cap & Net Worth: Kaken Pharmaceutical Co. Ltd (KKPCF)
Kaken Pharmaceutical Co. Ltd (PINK:KKPCF) has a market capitalization of $996.32 Million ($996.32 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #7921 globally and #4097 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kaken Pharmaceutical Co. Ltd's stock price $26.31 by its total outstanding shares 37868340 (37.87 Million).
Kaken Pharmaceutical Co. Ltd Market Cap History: 2020 to 2025
Kaken Pharmaceutical Co. Ltd's market capitalization history from 2020 to 2025. Data shows change from $1.32 Billion to $996.32 Million (-6.27% CAGR).
Kaken Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kaken Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Kaken Pharmaceutical Co. Ltd's market cap is 0.01 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.07x
Kaken Pharmaceutical Co. Ltd's market cap is 0.07 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.32 Billion | $89.23 Billion | $19.37 Billion | 0.01x | 0.07x |
| 2021 | $1.45 Billion | $74.98 Billion | $13.40 Billion | 0.02x | 0.11x |
| 2022 | $1.02 Billion | $76.03 Billion | $9.55 Billion | 0.01x | 0.11x |
| 2023 | $1.09 Billion | $72.98 Billion | $5.44 Billion | 0.01x | 0.20x |
| 2024 | $909.22 Million | $72.04 Billion | $8.03 Billion | 0.01x | 0.11x |
| 2025 | $996.32 Million | $94.03 Billion | $13.95 Billion | 0.01x | 0.07x |
Competitor Companies of KKPCF by Market Capitalization
Companies near Kaken Pharmaceutical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Kaken Pharmaceutical Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kaken Pharmaceutical Co. Ltd Historical Marketcap From 2020 to 2025
Between 2020 and today, Kaken Pharmaceutical Co. Ltd's market cap moved from $1.32 Billion to $ 996.32 Million, with a yearly change of -6.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $996.32 Million | +9.58% |
| 2024 | $909.22 Million | -16.54% |
| 2023 | $1.09 Billion | +6.57% |
| 2022 | $1.02 Billion | -29.72% |
| 2021 | $1.45 Billion | +10.35% |
| 2020 | $1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kaken Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $996.32 Million USD |
| MoneyControl | $996.32 Million USD |
| MarketWatch | $996.32 Million USD |
| marketcap.company | $996.32 Million USD |
| Reuters | $996.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.